Novo Integrated Sciences, Inc. (NVOS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.95 Million USD | 3.2% |
| 2022 | 4.79 Million USD | 25.54% |
| 2021 | 3.82 Million USD | 25.0% |
| 2020 | 3.05 Million USD | -13.1% |
| 2019 | 3.51 Million USD | 2.81% |
| 2018 | 3.42 Million USD | 14.97% |
| 2017 | 2.97 Million USD | 18.73% |
| 2016 | 2.5 Million USD | -7.34% |
| 2015 | 2.7 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 100.0% |
| 2009 | -1.87 Million USD | -126.17% |
| 2008 | -827.36 Thousand USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 896.89 Thousand USD | -32.26% |
| 2024 Q1 | 1.94 Million USD | 109.44% |
| 2024 Q2 | 1.32 Million USD | -31.89% |
| 2023 Q1 | 1.73 Million USD | 1981.31% |
| 2023 Q4 | 928.18 Thousand USD | -29.37% |
| 2023 FY | 4.95 Million USD | 3.2% |
| 2023 Q3 | 1.31 Million USD | 35.35% |
| 2023 Q2 | 970.9 Thousand USD | -44.19% |
| 2022 FY | 4.79 Million USD | 25.54% |
| 2022 Q1 | 1.26 Million USD | 29.28% |
| 2022 Q4 | -92.46 Thousand USD | -103.84% |
| 2022 Q3 | 2.4 Million USD | 98.04% |
| 2022 Q2 | 1.21 Million USD | -3.96% |
| 2021 Q1 | 811.45 Thousand USD | -1.22% |
| 2021 Q3 | 1.28 Million USD | 70.4% |
| 2021 Q4 | 979.64 Thousand USD | -23.49% |
| 2021 FY | 3.82 Million USD | 25.0% |
| 2021 Q2 | 751.44 Thousand USD | -7.39% |
| 2020 FY | 3.05 Million USD | -13.1% |
| 2020 Q1 | 915.66 Thousand USD | 11.19% |
| 2020 Q2 | 843 Thousand USD | -7.94% |
| 2020 Q3 | 478.25 Thousand USD | -43.27% |
| 2020 Q4 | 821.44 Thousand USD | 71.76% |
| 2019 Q1 | 883.53 Thousand USD | 6.0% |
| 2019 FY | 3.51 Million USD | 2.81% |
| 2019 Q4 | 823.52 Thousand USD | -11.71% |
| 2019 Q2 | 879.67 Thousand USD | -0.44% |
| 2019 Q3 | 932.71 Thousand USD | 6.03% |
| 2018 FY | 3.42 Million USD | 14.97% |
| 2018 Q4 | 833.55 Thousand USD | -7.91% |
| 2018 Q3 | 905.17 Thousand USD | 7.97% |
| 2018 Q2 | 838.32 Thousand USD | -0.91% |
| 2018 Q1 | 846.04 Thousand USD | -12.38% |
| 2017 FY | 2.97 Million USD | 18.73% |
| 2017 Q4 | 965.53 Thousand USD | 35.41% |
| 2017 Q3 | 713.05 Thousand USD | 10.6% |
| 2017 Q2 | 644.71 Thousand USD | -1.42% |
| 2017 Q1 | 654.02 Thousand USD | 2.16% |
| 2016 FY | 2.5 Million USD | -7.34% |
| 2016 Q4 | 640.21 Thousand USD | -5.33% |
| 2016 Q1 | 595.56 Thousand USD | 0.0% |
| 2016 Q2 | 595.56 Thousand USD | -0.0% |
| 2016 Q3 | 676.29 Thousand USD | 13.56% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | 2.7 Million USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | -2.12 Million USD | 0.0% |
| 2011 Q2 | - USD | 100.0% |
| 2010 Q1 | -1.87 Million USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 100.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 100.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | -1.87 Million USD | -126.17% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | -827.36 Thousand USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acadia Healthcare Company, Inc. | 682.6 Million USD | 99.274% |
| Addus HomeCare Corporation | 339.87 Million USD | 98.543% |
| AirSculpt Technologies, Inc. | 121.9 Million USD | 95.937% |
| Amedisys, Inc. | 457.07 Million USD | 98.916% |
| American Oncology Network, Inc. | 66.05 Million USD | 92.502% |
| Astrana Health, Inc. | 214.95 Million USD | 97.696% |
| Aveanna Healthcare Holdings Inc. | 595.43 Million USD | 99.168% |
| IMAC Holdings, Inc. | 3.84 Million USD | -28.688% |
| biote Corp. | 127.48 Million USD | 96.115% |
| Cryo-Cell International, Inc. | 22.9 Million USD | 78.374% |
| Cross Country Healthcare, Inc. | 432.06 Million USD | 98.854% |
| COMPASS Pathways plc | -242.93 Thousand USD | 2138.674% |
| DocGo Inc. | 178.95 Million USD | 97.232% |
| The Ensign Group, Inc. | 590.75 Million USD | 99.162% |
| Healthcare Services Group, Inc. | 251.45 Million USD | 98.03% |
| InnovAge Holding Corp. | 132.06 Million USD | 96.25% |
| Assure Holdings Corp. | -2.19 Million USD | 325.739% |
| The Joint Corp. | 107.14 Million USD | 95.378% |
| LifeStance Health Group, Inc. | 302.09 Million USD | 98.361% |
| Mobile-health Network Solutions Class A Ordinary Shares | -1.07 Million USD | 562.16% |
| ModivCare Inc. | 446.95 Million USD | 98.892% |
| NewGenIvf Group Limited | 1.68 Million USD | -194.492% |
| Option Care Health, Inc. | 981.22 Million USD | 99.495% |
| P3 Health Partners Inc. | 31.63 Million USD | 84.344% |
| P3 Health Partners Inc. | 31.63 Million USD | 84.344% |
| The Pennant Group, Inc. | 61.9 Million USD | 92.0% |
| Surgery Partners, Inc. | 529.4 Million USD | 99.064% |
| Syra Health Corp. Class A Common Stock | 1.41 Million USD | -250.784% |
| Talkspace, Inc. | 74.38 Million USD | 93.341% |
| Talkspace, Inc. | 74.38 Million USD | 93.341% |
| The Oncology Institute, Inc. | 59.57 Million USD | 91.686% |
| The Oncology Institute, Inc. | 59.57 Million USD | 91.686% |